Intellectus Partners’s GSK GSK Stock Holding History

Intellectus Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-451	Closed	-$23K	–	363
2018 Q3	$23K	Hold	451	–	–	0.01%	419
2018 Q2	$23K	Hold	451	–	–	0.01%	417
2018 Q1	$22K	Hold	451	–	–	0.01%	420
2017 Q4	$20K	Hold	451	–	–	0.01%	429
2017 Q3	$23K	Hold	451	–	–	0.01%	524
2017 Q2	$25K	Hold	451	–	–	0.01%	477
2017 Q1	$24K	Hold	451	–	–	0.01%	437
2016 Q4	$22K	Buy	+451	New	+$22.3K	0.01%	440

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return

Intellectus Partners's GSK Position: Q4 2018 in Review

Intellectus Partners sold out of GSK (GSK) in Q4 2018, closing a stake of 451 shares — an estimated $23K sold.

Intellectus Partners first reported a position in GSK in Q4 2016 and held it in 8 quarters. The position peaked at $25K in Q2 2017. 800 funds tracked by Wall St. Rank hold GSK as of Q4 2018.

Intellectus Partners reported no remaining GSK position as of Q4 2018 after selling out during the quarter.
Intellectus Partners sold 451 GSK shares in Q4 2018, an estimated $23K.
Intellectus Partners first reported a position in GSK in Q4 2016 and held it in 8 quarters.
Intellectus Partners's GSK position peaked at $25K in Q2 2017.
800 funds tracked by Wall St. Rank held GSK as of Q4 2018.

Based on Intellectus Partners's 13F filing for Q4 2018, filed 14 Feb 2019.